Introduction
Radiation therapy is a cornerstone treatment for head and neck cancers, including tumors of the nasopharynx, brain, and skull base. However, the auditory and vestibular systems are highly vulnerable to radiation damage. Radiation-induced hearing loss (RIHL) and dizziness are significant late effects that impair quality of life. This article explores these complications through the lens of otoneurology, emphasizing mechanisms, diagnosis, and management.
Pathophysiology of Radiation-Induced Hearing Loss
Hearing loss after radiation can be conductive, sensorineural, or mixed. Radiation damages the cochlear hair cells, the stria vascularis, and the auditory nerve. The organ of Corti is particularly radiosensitive. Fibrosis and vascular compromise lead to progressive sensorineural hearing loss, often bilateral and high-frequency. In otoneurology, this is classified as cochleopathy or retrocochlear pathology if the auditory nerve or brainstem is involved.
Middle ear complications such as otitis media with effusion or osteoradionecrosis of the ossicles cause conductive hearing loss. The onset may be delayed months to years after radiation exposure, making follow-up audiometry essential.
Radiation-Induced Dizziness and Vestibular Dysfunction
Dizziness after cranial irradiation results from damage to the vestibular end organs (semicircular canals, otoliths) or the vestibular nerve and central pathways. Vestibular schwannoma patients receiving stereotactic radiosurgery may develop acute or chronic imbalance. In otoneurology, electronystagmography (ENG) and video head impulse testing (vHIT) reveal reduced vestibular responses. Central vestibular dysfunction from temporal lobe or brainstem radiation can cause persistent dizziness and oscillopsia.
Radiation also induces endolymphatic hydrops mimicking Meniere's disease. The risk increases with higher cumulative doses and concurrent chemotherapy (e.g., cisplatin).
Clinical Presentation and Diagnosis
Patients report bilateral hearing loss, tinnitus, aural fullness, and vertigo or unsteadiness. Audiometry shows sensorineural hearing loss, often with a notch at 4-6 kHz. Speech discrimination scores may be poor. Vestibular testing includes caloric irrigation, rotary chair, and vestibular evoked myogenic potentials (VEMPs). Imaging with MRI is crucial to rule out tumor recurrence or radiation necrosis. Otoneurologic evaluation distinguishes peripheral from central causes, guiding rehabilitation.
Management and Rehabilitation
Prevention is paramount: intensity-modulated radiation therapy (IMRT) and cochlear dose constraints reduce cochlear toxicity. For established hearing loss, hearing aids or cochlear implants are options. Vestibular therapy including habituation and balance exercises helps dizziness. Diuretics and low-salt diets may alleviate hydrops-like symptoms. Corticosteroids are used for sudden worsening. Otoneurologists collaborate with audiologists and oncologists to optimize outcomes.
Prognosis
Radiation-induced hearing loss is typically irreversible and may progress over years. Dizziness may improve with central compensation but can be debilitating. Regular monitoring with pure-tone audiometry and vestibular assessments is recommended. Emerging research explores radioprotectants and stem cell therapy to preserve inner ear function.
Conclusion
The intersection of otoneurology and radiation oncology is critical in managing these complications. Early detection, dose limitation, and multidisciplinary care minimize disability. For patients undergoing cranial radiation, informed consent and long-term surveillance for hearing loss and dizziness are essential.